Clinical Trial Update: A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study of UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer was terminated, with results posted on 2024-06-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• UGN-102 (UGN-102)

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Bladder Cancer, Urothelial Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2024-06-06